Iovance raises 2026 revenue guidance to $350M–$370M, reports stronger real-world Amtagvi response rates

Filed July 2, 2026 · Period ending June 30, 2026 · ~1 min read

Key Changes

• high

  Full-year 2026 revenue guidance set at $350M–$370M, with Q2 2026 expected at $86M–$88M, reflecting ~45% YoY growth as Amtagvi and Proleukin sales scale.

  Exhibit 99.1 verify on EDGAR →
• high

  Real-world Amtagvi response rate of 44% (18/41 patients) exceeds pivotal trial's 31.4%, with 52% response in patients with two or fewer prior therapies, supporting earlier treatment use.

  Exhibit 99.1 verify on EDGAR →
• high

  Cash position of $319M as of March 31, 2026, with runway extending into 2028, incorporating revenue growth and August 2025 restructuring savings.

  Exhibit 99.1 verify on EDGAR →